Date of publication: June 25, 2021 Decision of the Secretary of Health: Approved Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report is produced to present all currently available evidence considered in continue reading : BNT162b2 (Pfizer-BioNTech COVID-19 Vaccine) for the prevention of COVID-19 (June Reassessment)
Janssen Ad26.COV2.S (COVID-19) Vaccine for the prevention of COVID-19 (June Reassessment)
Date of publication: June 25, 2021 Decision of the Secretary of Health: Approved Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of COVID-19 continue reading : Janssen Ad26.COV2.S (COVID-19) Vaccine for the prevention of COVID-19 (June Reassessment)
Sputnik V Gam-COVID-Vac COVID-19 Vaccine for the prevention of COVID-19 (June Reassessment)
Date of publication: July 30, 2021 Decision of the Secretary of Health: Approved Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of continue reading : Sputnik V Gam-COVID-Vac COVID-19 Vaccine for the prevention of COVID-19 (June Reassessment)
SARS-CoV-2 Vaccine (Vero Cell), Inactivated [CoronaVac] for the Prevention of COVID-19 (July Updates)
Date of publication: July 30, 2021 Decision of the Secretary of Health: Approved Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of continue reading : SARS-CoV-2 Vaccine (Vero Cell), Inactivated [CoronaVac] for the Prevention of COVID-19 (July Updates)